Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) EBIT (2016 - 2025)

Historic EBIT for KalVista Pharmaceuticals (KALV) over the last 9 years, with Q2 2025 value amounting to -$55.0 million.

  • KalVista Pharmaceuticals' EBIT fell 1356.93% to -$55.0 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$180.9 million, marking a year-over-year decrease of 7509.56%. This contributed to the annual value of -$188.0 million for FY2025, which is 3385.67% down from last year.
  • KalVista Pharmaceuticals' EBIT amounted to -$55.0 million in Q2 2025, which was down 1356.93% from -$44.2 million recorded in Q3 2024.
  • KalVista Pharmaceuticals' 5-year EBIT high stood at -$33.2 million for Q1 2024, and its period low was -$55.0 million during Q2 2025.